Whipping NF-κB to Submission via GADD45 and MKK7.
NF-κB protects malignant cells from death and therefore it was considered as a cancer treatment target. However, systemic NF-κB inhibition resulted in inflammation and other undesired outcomes. In this issue of Cancer Cell, Tornatore and colleagues solve this problem by targeting the GADD45:MKK7 module mediating NF-κB-induced survival of multiple myelomas.